Peter Rohmeiss

Therapeutic Administration of an Endothelin-A Receptor Antagonist after Acute Ischemic Renal Failure Dose-Dependently Improves Recovery of Renal Function

T. Knoll, K. Juenemann, M. Kirchengast, 2001, Journal of cardiovascular pharmacology.

Preferential COX-2 Inhibitor, Meloxicam, Compromises Renal Perfusion in Euvolemic and Hypovolemic Rats

T. Knoll, F. J. van der Woude, R. Birck, 2000, Nephron Experimental Nephrology.

Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

T. Slowinski, T. Quertermous, H. Neumayer, 1997, The Journal of clinical investigation.

Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist.

M. Schaub, S. Tullius, F. J. van der Woude, 1999, Transplantation.

Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats.

N. Gretz, H. Neumayer, C. Bauer, 1996, Cardiovascular research.

Improvement of postischemic acute renal failure with the novel orally active endothelin-A receptor antagonist LU 135252 in the rat.

T. Knoll, F. J. van der Woude, R. Birck, 1998, Journal of cardiovascular pharmacology.